Patents by Inventor Pan Zheng

Pan Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050172351
    Abstract: The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.
    Type: Application
    Filed: February 7, 2005
    Publication date: August 4, 2005
    Inventors: Yang Liu, Pan Zheng, Ping Lu, Bedrich Mosinger, Ken May
  • Patent number: 6875904
    Abstract: The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: April 5, 2005
    Assignee: The Ohio State University Research Foundation
    Inventors: Yang Liu, Pan Zheng, Ping Lu, Bedrich Mosinger, Ken May
  • Publication number: 20030106084
    Abstract: Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells.
    Type: Application
    Filed: April 10, 2002
    Publication date: June 5, 2003
    Inventors: Yang Liu, Pan Zheng, Xuefeng Bai, Xingluo Liu
  • Publication number: 20030095966
    Abstract: Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided In one embodiment, the method comprises administering a pharmaceutical composition comprising a biologically effective amount of an isolated and purified CD24 polypeptide, or a fusion protein comprising such polypeptide to a mammalian subject who is suspected of having an autoimmune disease. In another embodiment, the method comprises administering a pharmaceutical composition comprising a biologically effective amount of an anti-CD24 antibody or anti-CD24 Fab fragments to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells.
    Type: Application
    Filed: March 29, 2001
    Publication date: May 22, 2003
    Inventors: Yang Liu, Pan Zheng, Xue-Feng Bai
  • Publication number: 20020115209
    Abstract: The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.
    Type: Application
    Filed: September 20, 2001
    Publication date: August 22, 2002
    Inventors: Yang Liu, Pan Zheng, Ping Lu, Bedrich Mosinger, Ken May